ReviewThe Iowa orthopaedic journal2025
Recognition and Recurrence of Aneurysmal Bone Cyst Secondary to Giant Cell Tumor: A Case Series and Review Of The Literature.
Review in The Iowa orthopaedic journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aneurysmal bone cysts (ABCs) are rare, benign bone lesions with distinct genetic and pathological characteristics. Secondary ABCs arising from giant cell tumors (GCTs) are associated with higher recurrence rates compared to primary ABCs. This study aimed to evaluate recurrence rates and risk factors for primary ABCs, secondary ABCs in GCT, and GCTs, with a focus on radiologic and clinical predictors. Methods: This retrospective cohort study analyzed 44 patients with histologically confirmed primary ABC (n=24), secondary ABC in GCT (n=8), or GCT (n=12), treated surgically with adjuvants between 2010 and 2020. Tumors were staged using the Enneking/MSTS system, and recurrence rates were assessed using Kaplan-Meier survival analyses and Chi-square tests. The mean follow-up period was 49.4 months. Results: The overall recurrence rate was 11%, with a 5-year recurrence-free survival rate of 89%. Recurrence-free survival was 92% for primary ABCs, 92% for GCTs, and 75% for secondary ABCs. Significant risk factors included soft tissue extension in primary ABCs (p = 0.037) and mixed radiologic appearance in GCTs (p = 0.033). Secondary ABCs were more common in patients over 20 years and often presented with multiloculated cystic areas. Conclusion: Recurrence rates are similar among primary ABCs, secondary ABCs, and GCTs. However, secondary ABCs exhibit recurrence behaviors closer to GCTs, particularly in patients with advanced age and complex radiological features. These findings highlight the importance of meticulous tumor resection and the careful use of adjuvants to reduce the risk of recurrence.
Indexed as
Identifiers
40606728PMC12212323What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.